HOME >> BIOLOGY >> NEWS
Cell transplantation could restore cardiac function after heart attack

French authors of a research letter in this week's issue of THE LANCET describe the preliminary success of transplanting muscle stem-cells from the thigh to the heart to restore damaged cardiac tissue after heart attack.

The procedure was done in a 72-year-old man and resulted in improved left-ventricular and overall heart function. After the man's death 18 months later, the grafted post-infarction scar showed that the undifferentiated stem cells transplanted from his leg had evolved into well developed skeletal myotubes with a preserved contractile structure.

Lead author Albert Hagge from Hopital Europeen Georges Pompidou, Paris, France, comments: "Irrespective of the mechanism, these results lend support to the usefulness of myoblast therapy in a clinical setting, suggest that grafts have long-term viability, that there is formation of non-degenerated functional myotubes, and a phenotypic switch towards slow-twitch fibres that might allow them to sustain a cardiac workload over time."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
6-Feb-2003


Page: 1

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Pig-human transplantation not PERVerted
3. Cells from adult bone marrow can be converted into brain stem cells for transplantation
4. Heart and lung transplantation clinical trial results to be announced at ISHLT meeting
5. Hopkins researchers identify transplantation antigens among Sioux Indians
6. Transparent fish provide window on blood formation and marrow transplantation
7. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
8. Prize to Weizmann Institute professor for landmark work in stem cell transplantation
9. Islet cell transplantation for diabetes turns corner
10. 1st evidence that nuclear transplantation (therapeutic cloning) can eliminate tissue rejection
11. Improvement in some patients who underwent neuronal transplantation following stroke, according to study by University of Pittsburgh researchers

Post Your Comments:
(Date:5/20/2013)... 2013) - A novel vaccine study from ... research that will be unveiled at the American Association ... meeting takes place Monday, May 20 - Wednesday, May ... , "The main goal of a vaccine is ... pathogen that causes the disease", explained Dr. Hemachand Tummala, ...
(Date:5/19/2013)... at the University of California, Davis have engineered a ... for light. They report their findings today at ... Microbiology. , "In this work, we used synthetic biology ... carbon dioxide and light energy for growth) cyanobacterial metabolism ... Jordan McEwen, the lead researcher on the study. ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: